



# Phage Biocontrol of *Campylobacter jejuni* in Chickens Does Not Produce Collateral Effects on the Gut Microbiota

Philip J. Richards, Phillippa L. Connerton and Ian F. Connerton\*

Division of Food Sciences, School of Biosciences, University of Nottingham, Loughborough, United Kingdom

## OPEN ACCESS

### Edited by:

Steven C. Rieke,  
University of Arkansas, United States

### Reviewed by:

Catherine Maylin Loc-Carrillo,  
The University of Utah, United States  
Stephen Tobias Abedon,  
The Ohio State University,  
United States

### \*Correspondence:

Ian F. Connerton  
ian.connerton@nottingham.ac.uk

### Specialty section:

This article was submitted to  
Food Microbiology,  
a section of the journal  
Frontiers in Microbiology

**Received:** 26 November 2018

**Accepted:** 25 February 2019

**Published:** 12 March 2019

### Citation:

Richards PJ, Connerton PL and  
Connerton IF (2019) Phage Biocontrol  
of *Campylobacter jejuni* in Chickens  
Does Not Produce Collateral Effects  
on the Gut Microbiota.  
*Front. Microbiol.* 10:476.  
doi: 10.3389/fmicb.2019.00476

Bacteriophage biocontrol to reduce *Campylobacter jejuni* levels in chickens can reduce human exposure and disease acquired through the consumption of contaminated poultry products. Investigating changes in the chicken microbiota during phage treatment has not previously been undertaken but is crucial to understanding the system-wide effects of such treatments to establish a sustainable application. A phage cocktail containing two virulent *Campylobacter* phages was used to treat broiler chickens colonized with *C. jejuni* HPC5. *Campylobacter* counts from cecal contents were significantly reduced throughout the experimental period but were most effective 2 days post-treatment showing a reduction of 2.4 log<sub>10</sub> CFU g<sup>-1</sup> relative to mock-treated *Campylobacter* colonized controls. The administered phages replicated *in vivo* to establish stable populations. Bacteriophage predation of *C. jejuni* was not found to affect the microbiota structure but selectively reduced the relative abundance of *C. jejuni* without affecting other bacteria.

**Keywords:** bacteriophage, campylobacter, microbiota, chicken, biocontrol

## INTRODUCTION

*Campylobacter* ssp. cause foodborne illness worldwide (Kaakoush et al., 2015) and represent the most commonly reported zoonotic pathogens in the European Union with 246,307 confirmed cases of gastrointestinal illness in 2016 (European Food Safety Authority [EFSA], 2017). *Campylobacter jejuni* is the most common species causing human disease (83.6%), but the burden of disease caused by *Campylobacter coli* is also significant (8.5%) (European Food Safety Authority [EFSA], 2017). Both species readily colonize the poultry gut, where the impact on flock health and production parameters varies with husbandry practice and the colonizing organism (Gormley et al., 2014; Humphrey et al., 2015). Estimates of broiler chicken flock prevalence vary between nations with 0.6 to 13.1% in the Nordic countries up to 74.2–80% in other European countries (European Food Safety Authority [EFSA], 2010a). Source attribution studies have predicted that up to 80% of human illness is as a result of exposure to campylobacter arising from poultry sources (European Food Safety Authority [EFSA], 2010b). A recent source attribution study referenced at the point of exposure confirmed chicken meat as the most important source of *Campylobacter* enteric disease, with an estimated 65–69% of human campylobacteriosis cases (Ravel et al., 2017). Poultry meat contaminated with digesta during slaughter/processing therefore represents a significant risk to public health (Osmani et al., 2017).

Strict on-farm biosecurity measures to mitigate the *Campylobacter* colonization of poultry have been implemented in many countries, but these alone do not eliminate campylobacter from poultry. Additional to these efforts, intervention strategies have been developed to reduce the *Campylobacter* colonization levels of poultry, which have the potential to reduce human exposure if the reductions can be realized on poultry meat (Rosenquist et al., 2003; Newell et al., 2011). The use of *Campylobacter*-specific bacteriophages (commonly referred to as phages) to reduce the intestinal carriage of *Campylobacter* by broiler chickens is one such intervention that has shown promise in controlled trials (Loc Carrillo et al., 2005; Wagenaar et al., 2005; El-Shibiny et al., 2009) and in broiler house applications (Kittler et al., 2013). These studies have been conducted with phage applications of one or more phage to achieve reductions in the cecal counts of *Campylobacter* colonized chickens of approximately  $2 \log_{10}$  CFU  $g^{-1}$  (Carvalho et al., 2010; Connerton et al., 2011; Hammerl et al., 2014).

The use of multiple types of phage targeting different receptors in the form of phage cocktails offers the prospect of expanding the host range of the preparation whilst limiting the potential to develop resistance to all components of the cocktail (Chan et al., 2013). This has been explored experimentally using *Campylobacter*-specific phage cocktails containing either four (Fischer et al., 2013) or two phages (Hammerl et al., 2014). In both cases phages were selected from both Group II and Group III as classified by Sails et al. (1998). The classification was originally based on total genome size and morphology but it is now known that the two groups share little DNA similarity and generally have different host specificities (Javed et al., 2014; Jäckel et al., 2017). Group II and III *Campylobacter* bacteriophages are taxonomically classified as members of the *Myoviridae* subfamily *Eucampyvirinae*, which do not possess the genes required to form stable lysogens and therefore exhibit a lytic or virulent life cycle similar to most Myoviruses (Javed et al., 2014). *Campylobacter* phage isolated using *C. jejuni* and *C. coli* hosts may show some cross-species specificity within strains of *C. jejuni* and *C. coli* species but have not been demonstrated to infect other species in the *Campylobacter* genus, for example *C. lari*, *C. upsaliensis*, *C. fetus*, *C. Sputorum*, or *C. intestinalis* (Loc Carrillo et al., 2007). Neither have they been found to infect *Helicobacter pylori*, *Arcobacter butzleri*, *Citrobacter freundii*, *Salmonella enteritica* serovar Enteritidis, *Escherichia coli*, and *Pseudomonas aeruginosa* (Loc Carrillo et al., 2007). Therefore it may be anticipated that components of a *Campylobacter* phage cocktail would retain their specificity and not give rise to dysbiosis – a detrimental microbiota constitution that often arises post broad-spectrum antibiotic therapies (Dethlefsen et al., 2008). However, a recent study has suggested that exposure of the rat gut microbiome to a cocktail of commercial phage preparations active against *Salmonella enterica*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Proteus mirabilis*, *P. vulgaris*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *E. coli* results in dysbiosis with increased inflammation and gut permeability (Tetz et al., 2017). Bacteriophage mediated cell lysis has the potential to release lipopolysaccharides (endotoxin) from Gram-negative bacterial species that are potent inducers of proinflammatory cytokines

in animals and in humans (Medzhitov, 2007). Exposure to a phage cocktail targeting multiple Gram-negative species may well elicit such a response, although it is reported that targeted virulent *E. coli* bacteriophages release less endotoxin than  $\beta$ -lactam antibiotics (Dufour et al., 2017), and that the phage tail adhesin protein Gp12 can bind free lipopolysaccharide to counteract the inflammatory effect (Miernikiewicz et al., 2016). Typically the lipopolysaccharides of Gram-negative bacteria are composed of an outer membrane anchored lipid A substituted with a core polysaccharide structure attached to a set of repeating O-chain subunits. However, *C. jejuni* synthesizes a core oligosaccharide without the repeating O-chain, which is referred to as lipooligosaccharide (Karlyshev et al., 2005).

In this study we demonstrate that *Campylobacter* phage affect the target host bacteria without provoking intestinal dysbiosis, when phages are administered to broiler chickens at therapeutic doses.

## METHODOLOGY

### Bacterial Strains and Growth Media

*Campylobacter* were isolated and enumerated by direct plating on modified Cefoperazone Charcoal Deoxycholate Agar (mCCDA) selective medium (Oxoid, Basingstoke, United Kingdom) with addition of cefoperazone and amphotericin B selective supplement (Oxoid) using standard techniques. *C. jejuni* HPC5 was isolated from the cecal content of a commercial broiler chicken in the United Kingdom (Loc Carrillo et al., 2005; NCBI accession CP032316). The universal bacteriophage host strain *C. jejuni* PT14 was used to propagate *Campylobacter* bacteriophages (Brathwaite et al., 2013; NCBI accession CP003871). *C. coli* NCTC 12668 was used to discriminate group II and III bacteriophages (Frost et al., 1999). *C. jejuni* HPC5 for the inoculation of broiler chickens and campylobacter for the production of bacterial lawns were cultured on horse blood agar (Blood agar base No 2; Oxoid) with addition of plus 5% (v/v) defibrinated horse blood, (TCS, Buckingham, United Kingdom) under microaerobic conditions (5% O<sub>2</sub>, 5% H<sub>2</sub>, 10% CO<sub>2</sub>, 80% N<sub>2</sub>, produced by the evacuation and replacement technique) at 42°C for 24 h.

### Bacteriophages and Propagation

*Campylobacter*-specific bacteriophages CP20 and CP30A were isolated from commercial broiler chicken excreta collected in the United Kingdom in 2001. Bacteriophages were isolated by making a 10% suspension of excreta in SM buffer (50 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 8 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, and 0.01% gelatin; Sigma Aldrich, Gillingham, United Kingdom). This was incubated at 4°C with agitation, for 24 h followed by centrifugation at 13,000 × *g* for 5 min to remove bacteria. The resulting supernatant was filtered through a 0.2  $\mu$ m filter (Minisart, Sartorius, Goettingen, Germany) to remove any remaining bacteria.

When screening for the presence or absence of bacteriophage, 10  $\mu$ l filtrate aliquots were applied to bacterial lawns of *C. jejuni* PT14 prepared using the soft agar overlay method

as previously described (Connerton et al., 2004). Bacteriophage were propagated by complete plate lysis and recovered in SM buffer before filtration (0.2  $\mu\text{m}$  filter) and concentration by centrifugation at  $37,000 \times g$ .

CP20 (NCBI nucleotide accession MK408758) corresponds to a group II *Campylobacter* bacteriophage and CP30A (NCBI nucleotide accession JX569801) a group III based on genome sizes, capsid morphologies determined by transmission electron microscopy and genomic DNA sequences (Scott et al., 2007a; Siringan et al., 2011, 2014; Javed et al., 2014; Brathwaite et al., 2015).

## Experimental Birds

Commercial *Campylobacter*-free male Ross 308 broiler chicks were obtained as hatchlings (PD Hook, Oxfordshire, United Kingdom). Birds were housed in a controlled environment in individual pens under strict conditions of biosecurity. Temperatures were as outlined in the Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes. Birds were provided with commercial broiler diets (starter, grower, and finisher) and water *ad libitum* for the duration. The birds were weighed and randomly assigned to 3 groups at 14 days of age. These were: Control group consisting of *Campylobacter*-free sentinel birds, Group Cj\_phg, consisting of *Campylobacter* infected birds to be administered with phage and Group Cj, consisting of *Campylobacter* infected birds to be administered with placebo instead of phage (mock treatment). Cloacal swabs were taken on day 14 and tested for *Salmonella* by direct plating on Xylose-Lysine desoxycholate agar (XLD) agar (Oxoid) and for *Campylobacter* by direct plating on mCCDA agar. Excreta samples, from the same day, were tested for *Campylobacter* phage (see below) and for *Salmonella* by enrichment in Rappaport-Vassiliadis soya peptone broth (Oxoid) then plating on Xylose-Lysine desoxycholate agar (XLD) agar (Oxoid). *C. jejuni* HPC5 has previously been demonstrated to establish intestinal colonization of Ross 308 broiler chickens at 20 days of age within 48 h of oral gavage, and to maintain colonization levels without significant differences in cecal counts over 15 days (Loc Carrillo et al., 2005; Connerton et al., 2018). Four days post oral gavage was selected for phage administration to ensure intestinal colonization, and that any variation in the cecal counts would be evident over the period of the experiment. Birds from Cj and Cj\_phg groups were colonized with *C. jejuni* HPC5 at 20 days of age. Each bird received  $7 \log_{10}$  CFU *C. jejuni* in 1 ml of PBS (phosphate buffered saline) by oral gavage. Phages were administered to Group Cj\_phg as a single dose of  $\log_{10}$  7 PFU of CP20 and CP30A combined in 1 ml of 30%  $\text{CaCO}_3$  (antacid) by oral gavage at 24 days of age. Group Cj were administered with 1 ml of 30%  $\text{CaCO}_3$  as a placebo at 24 days of age. Five birds were sacrificed at 24 h intervals from 25 to 29 days of age following administration of phage or placebo. The ceca, ileum, and colon of the birds were first separated by ligature and then removed by sterile dissection. The luminal contents were collected for *Campylobacter* and bacteriophage isolation as described below and aliquots stored at  $-80^\circ\text{C}$  for DNA extraction.

## Enumeration of Campylobacters

Serial dilutions of digesta were made in maximum recovery diluent (MRD; Oxoid) and enumerated using the Miles and Misera technique on mCCDA agar with 2% (w/v) additional agar to reduce swarming. Plates were incubated under microaerobic conditions at  $42^\circ\text{C}$  for 48 h before typical *Campylobacter* colonies were counted.

## Enumeration of Bacteriophages

Bacteriophages were recovered by making a 10% suspension of chicken digesta in SM buffer as described above. To enumerate bacteriophage CP20 and CP30A in the phage treated groups, independent lawns of *C. jejuni* HPC5 and *C. coli* NCTC 12668 were prepared. The *C. coli* strain NCTC 12668 was used as a second host because it was sensitive to CP20 but not CP30A, which allowed discrimination of the two phages administered. The CP30A titers were obtained by subtraction of the CP20 titer on *C. coli* 12668, from the total phage count on the *C. jejuni* HPC5 host, which was sensitive to both phages. Serial dilutions of intestinal contents were prepared in SM buffer and applied to these lawns as 10  $\mu\text{l}$  spots in triplicate. The plates were then incubated for 24 h at  $42^\circ\text{C}$  under microaerobic conditions.

## Acquisition of Bacteriophage Resistance

In order to establish the frequency of resistance to bacteriophages post-intervention, single colonies were lifted from the primary isolation plates onto which cecal content from all phage-treated and mock-treated control birds had been inoculated. Three colonies per cecal sample were picked for each phage-treated bird and subcultured on horse blood agar plates. Bacterial lawns were prepared from successful subcultures and CP20 and CP30A phage were applied at a range of dilutions from 1 to 3  $\log_{10}$  PFU to establish if resistance had been acquired with respect to the efficiency of plating.

## DNA Isolation


DNA was isolated from both ileal and cecal content using the Mobio PowerSoil kit (now QIAGEN Ltd., Manchester, United Kingdom). The method used is as described in the Human Microbiome Project SOP for processing of stool Specimens (see Manual of Procedures for Human Microbiome v12, section 7.7 onward<sup>1</sup>).

## Microbiome Analysis

The V4 regions of the bacterial 16S rRNA genes were PCR amplified using the primers 515f (5' GTGCCAGCMGCCGCGGTAA 3') and 806r (5' GGAC TACHVGGGTWTCTAAT 3') (Caporaso et al., 2011). Amplicons were then sequenced on the Illumina MiSeq platform using  $2 \times 250$  bp cycles. The 16S rRNA gene sequences were quality filtered and clustered into operational taxonomic units (OTUs) in Mothur (Schloss et al., 2009) using the Schloss lab. MiSeq SOP<sup>2</sup> (Kozich et al., 2013). Batch files of Mothur commands used

<sup>1</sup>[http://hmpdacc.org/resources/tools\\_protocols.php](http://hmpdacc.org/resources/tools_protocols.php)

<sup>2</sup>[https://www.mothur.org/wiki/MiSeq\\_SOP](https://www.mothur.org/wiki/MiSeq_SOP), (accessed 2018-10-05).



in this study are available at: <https://github.com/PJRichards>. Post-processing rarefaction curves were plotted to assess sampling effort (**Supplementary Figures S1–S3**). Based on these observations the Day 1 (1dpt) ileum communities and two further ileum communities (Group Cj: Day 2 replicate 2; Group Cj\_phg: day 4 replicate 4) were judged as having insufficient depth, and were therefore excluded from the analysis. No template controls were included in the analysis.

Raw sequence data are deposited in the NCBI database within the Bioproject PRJNA506577 under the SRA study SRP170194.

## Ethics Statement

All experimental animal work was performed in accordance with United Kingdom and EU law. This study was approved by the Local Ethics Committee of the University of Nottingham and performed under Home Office license.

## Statistical Analysis

The article was written in R 3.5.1 (R Core Team, 2018) and Rmarkdown 1.10.8 (Allaire et al., 2018; Xie et al., 2018) using Rstudio 1.1.456 (RStudio Team, 2015). R code used to make the figures/tables presented here are available at: [https://github.com/PJRichards/Richards\\_phage\\_microbiota](https://github.com/PJRichards/Richards_phage_microbiota). **Figure 3** was drawn in R using code adapted from Torondel et al. (2016) and kindly made available at: <http://userweb.eng.gla.ac.uk/umer.ijaz>. OTUs discriminatory between communities were identified using LEfSE (Segata et al., 2011). Commonality of 16S rDNA sequences of OTUs discriminative of phage-treated (Group Cj\_phg) and untreated birds (Group Cj) with other trials performed in our

laboratory were determined using stand-alone ncbi-blast-2.7.1+ (Zhang et al., 2000)<sup>3</sup>.

## RESULTS

### Dual *Campylobacter* Bacteriophage Treatment of Reduces Levels of *Campylobacter jejuni* Colonization

*Campylobacter* were enumerated using standard culture methods from intestinal luminal contents collected from the ileum, ceca, and colon of all birds. High levels of *Campylobacter* were recovered from all digesta collected from *C. jejuni* colonized birds (Group Cj) throughout the 5-day period of the experiment (mean  $\log_{10}$  CFU  $g^{-1}$ : ileum 6.289, ceca 8.000, colon 7.452 for  $n = 25$ ). A control group comprising of a cohort of non-colonized sentinel birds confirmed the effectiveness of the biosecurity measures adopted as they remained free of *Campylobacter* and phage contamination.

Co-administration of a single phage dose containing CP20 ( $7 \log_{10}$  PFU) and CP30A ( $7 \log_{10}$  PFU) 4 days after *Campylobacter* exposure at 24 days of age, significantly reduced *C. jejuni* numbers in the ceca of phage-treated birds (Group Cj\_phg) compared to mock-treated birds throughout the period of the experiment ( $p \leq 0.032$ ; **Figure 1A**). The phages were most effective 2 days post-treatment (dpt), resulting in a reduction in *C. jejuni* numbers of  $2.365 \log_{10}$  CFU  $g^{-1}$  in Group Cj\_phg compared to *C. jejuni* colonized controls in Group Cj.

<sup>3</sup><https://ftp.ncbi.nlm.nih.gov/blast/executables/LATEST/>

After this time, the numbers of *C. jejuni* in Group Cj\_phg birds increased but remained significantly lower than the levels observed from mock-treated birds (Group Cj) by  $1.321 \log_{10}$  CFU  $g^{-1}$  after 5 days.

Phage treatment was most effective in the cecum, the organ that represents the greatest biomass of digesta and reservoir of *C. jejuni*. However, treatment was also effective in reducing *C. jejuni* in the ileum ( $p = 0.044$  and  $0.008$  at 2 and 3 dpt, respectively) and the colon at all days excluding 2 dpt ( $p \leq 0.041$ ; **Figure 1E**). The reductions in *Campylobacter* counts were not as great as those observed for the ceca, with a maximum reduction in the ileum of  $1.359 \log_{10}$  CFU  $g^{-1}$  at 3 dpt and a maximum reduction in the colon of  $1.740 \log_{10}$  CFU  $g^{-1}$  also at 3 dpt (**Figures 1D,E**). Bacteriophages were enumerated over the 5 day trial period and were detected in the cecal contents of all 5 birds treated in Group Cj\_phg from 24 h after administration (**Figures 1B,C**). The CP20 phage titre recovered from cecal contents of the treated birds remained stable over time (mean  $5.738 \log_{10}$  PFU  $g^{-1}$ ;  $SD$  0.460; **Figure 1B**), confirming that the phage were replicating *in vivo*. Similarly, the mean CP30A titre was  $5.708 \log_{10}$  PFU  $g^{-1}$  ( $SD$  0.517; **Figure 1C**) confirming the two phages co-exist without competitive exclusion. The levels of phages recovered


from ileum and colon contents also remained stable over the course of the experiment (**Supplementary Figure S4**).

## Bacteriophage Resistance Post Treatment

The overall levels of phage resistance (isolates resistant to one or both phage) in *C. jejuni* HPC5 isolates in Group Cj\_phg was approximately 10% ( $n = 7/67$ ) of the strains recovered post-treatment. Of these, three (4.5%) were resistant to both CP20 and CP30A phages whilst one (1.5%) was resistant to CP20 but not CP30A and three (4.5%) were resistant to CP30A only. No phage resistance was detected in the *C. jejuni* recovered from birds that had not received phage ( $n = 32$ ).

## Bacteriophage Predation of *Campylobacter jejuni* Does Not Affect Microbiota Structure

The  $\alpha$ -diversity (inverse Simpson index) of the cecal or ileal microbiota of bacteriophage-treated birds (Group Cj\_phg) were not significantly different to those from mock-treated birds (Group Cj) ( $p \geq 0.095$  and  $\geq 0.841$ , respectively; **Figures 2A,C**). There was no difference in the richness (Chao) of the cecal



microbiota between 1 and 4 dpt ( $p \geq 0.151$ ) or the ileum microbiota at any time ( $p \geq 0.548$ ; **Figures 2B,D**). The Chao-richness of the cecal microbiota of bacteriophage-treated birds (Group Cj\_phg) was significantly different from mock-treated birds (Group Cj) by 5 dpt ( $p = 0.032$ ; **Figure 2B**).


## Exposure to *Campylobacter*-Phage Selectively Reduces Proportions of *C. jejuni* Without Affecting the Wider Microbiota

Throughout the experiment the predominant bacterial phylum present in the ileal lumen was the Firmicutes with a median relative abundance (RA) of 83.091% (**Supplementary Figure S5A**). There were no differences in relative abundance between age-matched bacteriophage-treated (Group Cj\_phg) and mock-treated birds (Group Cj) in this phylum ( $p \geq 0.063$ , Wilcoxon test; **Supplementary Figure S5A**). The next most abundant phylum are the Proteobacteria where a difference at 4 dpt was observed ( $p = 0.016$ ), but not on any other day ( $p \geq 0.730$ , Wilcoxon test; **Supplementary Figure S5A**). Phyla-level composition of the cecal microbiotas of both groups were likewise dominated by Firmicutes (median 90.620% RA), and to a much lesser extent Proteobacteria (4.747% RA) (**Supplementary Figure S5B**). However, there was no difference in the relative abundance of

Firmicutes or Proteobacteria between phage-treated (Group Cj\_phg) and mock-treated birds (Group Cj) at any time post-treatment ( $p \geq 0.178$ ,  $t$ -test; and  $p \geq 0.151$ , Wilcoxon test; respectively).

At the OTU level, phage treatment did not affect the  $\beta$ -diversity (Bray Curtis distance) between communities of ileal lumen bacteria from age-matched phage-treated (Group Cj\_phg) and mock-treated birds (Group Cj) at any time point ( $p = 0.106$ ; AMOVA; **Supplementary Figure S6A**). The 11 most abundant OTUs in the ileum lumen are shown in **Figure 3A**. After the OTUs were filtered to include only those  $\geq 1\%$  of total reads, the only discriminative OTU between phage-treated and mock-treated birds identified using LEfSE (Segata et al., 2011) was OTU0013 [*Campylobacter* (100)] at 3 dpt ( $p = 0.009$ ).

The 11 most abundant OTUs in the cecal lumen are shown in **Figure 3B**. For populations of cecal bacteria the  $\beta$ -diversity was not different at 1 to 4 dpt ( $p \geq 0.088$ , **Supplementary Figure S6B**). However, bacterial populations could be distinguished at 5 dpt ( $p = 0.021$ ). At 5 dpt OTU0009 [Clostridiales\_unclassified (100)] was the sole discriminative OTU between the treatments ( $p = 0.027$ ; LEfSE; **Supplementary Figure S7D**), which was present in significantly greater proportions in the mock-treated birds (Group Cj) relative to phage-treated birds (Group Cj\_phg) (mean % RA = 1.211 and 6.668, respectively) (**Figure 3A**). Previous work from our laboratory identified an OTU with 100% DNA sequence



identity to OTU0009 as being associated with *Campylobacter*-colonized birds [see OTU0073 in Connerton et al. (2018)]. Discriminative analysis of the cecal communities associated a greater abundance of *Campylobacter* (OTU0013) with the mock-treated birds (Group Cj) at 3 and 4 dpi ( $p < 0.047$ ; **Supplementary Figures S7B,C**, respectively). A positive association was observed between phage-treated (Cj\_phg) birds at 1 dpt and OTUs 0006 and 0021, representing Clostridium IV (98) and Clostridiales\_unclassified (100), respectively ( $p = 0.047$ ; **Supplementary Figure S7A** and **Figure 3B**).

At 5 dpt the bacterial communities of the ceca or ileum of *Campylobacter*-free sentinel control birds could not be distinguished from mock-treated *Campylobacter*-colonized birds (Group Cj,  $p > 0.05$ ; **Supplementary Figures S6A,B**), but cecal populations of bacteria in the phage-treated birds (Group Cj\_phg) could be distinguished from non-colonized control birds ( $p = 0.014$ ). Correspondingly, the OTUs that are associated with phage-treated birds (Group Cj\_phg) are OTU0006 Clostridium IV (98) and OTU0009 Clostridiales\_unclassified (100), which were also identified as discriminating phage-treated birds from mock-treated birds at 1 and 5 dpt, respectively (**Supplementary Figure S8B**). Although there was no difference in the  $\beta$ -diversity of non-colonized and mock-treated colonized birds in these cohorts, as expected OTU0013, representing *Campylobacter* (100), showed association with colonized birds, but conversely OTU0031, *Bifidobacterium* (100), showed association with the non-colonized control birds (**Supplementary Figure S8A**). This observation is also consistent with our previous study which demonstrates the differential association of an OTU with 100% DNA sequence identity with non-colonized birds compared to those 2 days post-colonization with *C. jejuni* at 20 days of age (NCBI database SRA study SRP133552; Connerton et al., 2018).

Interestingly, the low diversity of the ileal bacterial communities, relative to the cecal microbiota (see **Figures 2A,B**), is revealed in the observation that the top 11 most abundant OTUs across all ileal communities constitute 90.754% of reads, whereas the top 11 most abundant OTUs across all cecal communities account for a lower quotient of 48.670% reads (**Figures 3A,B**). We note that ileal samples showed some similarity to no template controls at phyla level (**Supplementary Table 1**), and that there was notable correspondence in the  $\gamma$ -proteobacteria [*Escherichia/Shigella* (100)] among the top 11 most abundant OTUs from ileal and cecal samples and the most abundant kitome/contaminant OTUs (**Figures 3A,B**; **Supplementary Table 2**).

## DISCUSSION

The results described here provide further evidence of the efficacy of phage treatment to reduce the *Campylobacter* colonization of chickens. It has been widely suggested that an advantage of phage biocontrol over antibiotic use or other broad-spectrum types of therapy against pathogens that inhabit the intestinal tract, is the specificity of the bacteriophage selected for a particular host (Sulakvelidze and Barrow, 2004; Sulakvelidze and Kutter, 2004).

This specificity is presumed to avoid the possibility of causing dysbiosis but recently this assumption has been challenged using a multi-phage treatment to affect collateral changes in the composition of the microbiota of rats with decreases in the abundance of *Blautia*, *Catenibacterium*, *Lactobacillus*, and *Faecalibacterium* species, and increases in the abundance of *Butyrivibrio*, *Oscillospira*, and *Ruminococcus* (Tetz et al., 2017). This is in contrast to directed studies using simulated gut microbial consortia (duodenum and ileum) containing a specific *Escherichia coli* as a bacteriophage target, where the impact of phage therapy was compared with ciprofloxacin treatment (Cieplak et al., 2018). Bacteriophage and antibiotic therapies were equally as effective in reducing the target *Escherichia coli* population by 2 to 3  $\log_{10}$  CFU  $\text{ml}^{-1}$  but notably the bacteriophage treatment had no measurable impact on non-target bacteria.

Although *Campylobacter* phages selected for the biocontrol of campylobacter in chickens appear to be confined to replication in *C. jejuni* and *C. coli* as hosts (Loc Carrillo et al., 2007), this discrimination had not previously been verified from the intestinal microbiota of *Campylobacter* colonized chickens. Frequency and abundance estimates of campylobacters and phages recovered from the ceca of commercial broiler chickens support the contention that production birds are often exposed to phage, and that phage presence coincides with a reduction in the mean *Campylobacter* cecal counts by approximately 1.8  $\log_{10}$  CFU  $\text{g}^{-1}$  (Atterbury et al., 2005). However, this study also demonstrated that phage which replicate on *Campylobacter* could be recovered in the absence of culture detectable *Campylobacter* host bacteria. The study left an open question as to whether the presence of phage under certain circumstances can drive *Campylobacter* populations below the culture detection limit ( $<2 \log_{10}$  CFU  $\text{g}^{-1}$ ) or that phage infecting campylobacters could also replicate on alternative host bacteria present in the microbiota of chickens. Further motivation for the current study was to establish whether phage therapy under these circumstances constitutes a minimal targeted intervention that utilizes biocontrol agents that are not detrimental to the intestinal microbiota of farmed chickens, and to which consumers are already exposed.

Phage therapy of *C. jejuni* colonized chickens produced significant reductions in intestinal *C. jejuni* counts compared to mock-treated controls over 5 days. However, the introduction of the phages did not affect the structures of the cecal or ileal microbiotas of the birds based on calculations of  $\alpha$ -diversity (inverse Simpson index). The richness (Chao) of the microbiota remained similarly indistinguishable until 4 dpt. At the phyla level no difference in the abundance of the major components were observed for the cecal microbiotas representing the greatest biomass, and at only one time point was any difference observed post-phage treatment for the ileal microbiotas (4 dpt). Analysis of differences in the relative abundance between phage-treated and mock-treated ileal and cecal community OTUs highlights significant differences in OTU0013 that represents the phage therapy target, *C. jejuni*.

Additional to this, the cecal community member OTU0009 (Clostridiales\_unclassified) showed significantly greater proportions in the mock-treated birds relative to phage-treated birds, as had previously been identified on the basis of the association of a DNA sequence identical OTU with *Campylobacter*-colonized birds (Connerton et al., 2018). The consistent association could be indicative of a key reliance for the corresponding clostridial organism(s) on high levels of *Campylobacter* colonization of the chicken gut. These observations further the idea that campylobacters can act as a hydrogen sink to improve the growth and competitive standing of specific clostridia (Kaakoush et al., 2015). The *Bifidobacterium* OTU0031 showed association with non-colonized sentinel birds, which is in contrast to 16S rRNA qPCR data reported by Thibodeau et al. (2015) that showed an increase in the molecular detection of *Bifidobacterium* sp. upon *C. jejuni* colonization. The authors noted that *Bifidobacterium* had previously been reported to hinder *C. jejuni* colonization (Ding et al., 2005; Santini et al., 2010), and that subtle effects may occur during *C. jejuni* colonization of chickens.

We observed the emergence of phage resistant *C. jejuni* post-phage treatment in this study as reported previously (Loc Carrillo et al., 2005; El-Shibiny et al., 2009; Fischer et al., 2013; Hammerl et al., 2014). We did not recover any phage resistant *C. jejuni* from the non-phage treated chickens despite the propensity of *C. jejuni* to undergo phase variation in genes leading to phage resistance (Aidley et al., 2017), and suggesting the observed phage escape mutation frequency of 10% in this experiment was a consequence of selection due to phage predation. The observed phage resistance frequency is within those reported previously of 1–14% (Loc Carrillo et al., 2005; El-Shibiny et al., 2009; Carvalho et al., 2010; Fischer et al., 2013; Hammerl et al., 2014). The phage treatment of chickens to reduce *Campylobacter* colonization has been demonstrated to be most effective over a 2–3 day period post-treatment (Loc Carrillo et al., 2005; El-Shibiny et al., 2009), since thereafter *Campylobacter* populations begin to recover. The continued impact of *Campylobacter* phage predation on the wider intestinal microbiota could not be assessed within the treatment timeframe examined in the current experiment (Connerton et al., 2018). However, when the time to slaughter after phage therapy was extended, the cecal *Campylobacter* levels were not reported to achieve the levels observed in non-treated controls (Fischer et al., 2013). This is likely due to reduced competitive fitness of the resistant types as described previously (Loc Carrillo et al., 2005; Scott et al., 2007a,b), and supports the supposition of Wagenaar et al. (2005) that the release of virulent *Campylobacter* phages into the environment would not constitute any greater risk.

Bacteriophage CP20 is a group II phage based on genome size and DNA sequence similarities. Group II phage are generally flagellotropic that require the host to be motile with a functional flagellar (Coward et al., 2006; Scott et al., 2007a,b; Baldwinsson et al., 2014; Lis and Connerton, 2016; Liang and Connerton, 2018). CP30A is a group III phage that in common with this phage group exhibits dependence on capsular polysaccharide

structures (Sørensen et al., 2011; Lis and Connerton, 2016). The post-phage treatment *C. jejuni* isolates we identified as resistant to both phage classes will be of interest to examine with respect to their ability recolonize chickens and the nature of the mutation. Although we note they remain a minority population within the chicken gut even in the presence of bacteriophage controlling the wild type *C. jejuni* populations. These bacteria are likely at a competitive disadvantage to the wild type.

We have rigorously examined the microbiota of *Campylobacter* colonized chickens treated with either phages or a placebo to provide strong evidence for the lack of any collateral effect on the gut microbiome.

## DATA AVAILABILITY

The datasets generated for this study can be found in NCBI, NCBI Bioproject PRJNA506577 under the SRA study SRP170194.

## AUTHOR CONTRIBUTIONS

IC designed the experiments. PR, PC, and IC executed the experiments, analyzed the data, and prepared the manuscript.

## FUNDING

This work was supported by the Biotechnology and Biological Sciences Research Council (Grant No. BB/I024682/1), United Kingdom.

## ACKNOWLEDGMENTS

The technical assistance of Nicola Cummings is gratefully acknowledged.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2019.00476/full#supplementary-material>

**FIGURE S1** | Rarefaction curves indicating coverage of *Campylobacter*-colonized (experimental) cecal bacterial communities. 16S rDNA bacterial communities from: (A) 1 day post-treatment (dpt); (B) 2 dpt; (C) 3 dpt; (D) 4 dpt; (E) 5 dpt. Cohort: (i) Group Cj (ii) Group Cj\_phg.

**FIGURE S2** | Rarefaction curves indicating coverage of *Campylobacter*-free non-colonized (control) cecal bacterial communities. 16S rDNA bacterial communities from *Campylobacter*-free non-colonized control birds at 29 days-old, equivalent to 5 days post-treatment.

**FIGURE S3** | Rarefaction curves indicating coverage of ileal bacterial communities. 16S rDNA bacterial community from: (A) 2 day post-treatment (dpt); (B) 3 dpt; (C) 4 dpt; (D) 5 dpt. The non-phage treated cohort (Group Cj) are shown in panels Ai to Di, and the phage treated cohort (Group Cj\_phg) in panels Aii to Dii.



**FIGURE S4** | *Campylobacter* phage titers in the ileum and colon post-treatment. Phage tiers were determined for CP20 (A) and CP30A phage (B) from ileal content and colon content (C), CP20; (D), CP30A). Filled squares indicate mean. Error bars indicate standard deviation.

**FIGURE S5** | Stacked bar chart showing phyla-level microbiota composition for ileal and cecal communities. OTUs were filtered so that only Phyla present in more than one ileal or cecal community are included in the analysis. Figures in parenthesis in the key indicate bootstrap values for that taxonomic assignment generated in Mothur. All taxa shown in the key were detected in the ileum lumen including those of low abundance (A). However, note that only Actinobacteria, Bacteria\_unclassified, Bacteroidetes, Firmicutes, and Proteobacteria phyla were detected in cecal communities (B).

**FIGURE S6** | Relationship between communities of gut bacteria from phage-treated and mock-treated birds. PCoA plot of Bray-Curtis distance between A) ileal ( $R^2 = 0.41$ ; A,B) cecal communities ( $R^2 = 0.75$ ; B).

**FIGURE S7** | Cecal bacterial taxa responsive to *Campylobacter*-phage treatment. OTUs were filtered to only include those representing at least 1% of the total reads

before all communities were randomly subsampled an equal depth for unbiased comparison. Discriminatory OTUs were then described between age-matched groups using LEfSE. LDA refers to Linear Discriminant Analysis. 1 dpt (A), 3 dpt (B), 4 dpt (C), 5 dpt (D). There were no differential OTUs at 2 dpt.

**FIGURE S8** | Gut bacterial taxa responsive to *Campylobacter*-colonization at 5 days post-treatment. OTUs were filtered as described for **Supplementary Figure S7** and discriminatory OTUs identified using LEfSE. LDA refers to Linear Discriminant Analysis. Control-Group Cj comparison (A), Control-Group Cj\_phg comparison (B).

**TABLE S1** | Description of phyla associated with no template controls. Due to potential for low biomass and dominant contaminant profile from ileum samples the kitome microbiota profile is included. Table text in parenthesis indicates Mothur taxonomy bootstrap values. Samples: kitome for all samples, excluding 1 dpt (kit Ai and kit Aii); kitome for 1 dpt (kit B); sequencing negative control for all samples, excluding 1 dpt (seq Ai and seq Aii); sequencing negative control for 1 dpt (seq B).

**TABLE S2** | Description of top 10 OTU associated with no template controls. Table text in parenthesis indicates Mothur taxonomy bootstrap values.

## REFERENCES

- Aidley, J., Sørensen, M. C. H., Bayliss, C. D., and Brøndsted, L. (2017). Phage exposure causes dynamic shifts in the expression states of specific phase-variable genes of *Campylobacter jejuni*. *Microbiology* 163, 911–919. doi: 10.1099/mic.0.000470
- Allaire, J., Xie, Y., McPherson, J., Luraschi, J., Ushey, K., Atkins, A., et al. (2018). *Rmarkdown: Dynamic Documents for R*. Available at: <https://rmarkdown.rstudio.com>.
- Atterbury, R. J., Dillon, E., Swift, C., Connerton, P. L., Frost, J., Dodd, C. E., et al. (2005). Correlation of *Campylobacter* bacteriophage with reduced presence of hosts in broiler chicken ceca. *Appl. Environ. Microbiol.* 71, 4885–4887. doi: 10.1128/AEM.71.8.4885-4887.2005
- Baldvinsson, S. B., Sørensen, M. C. H., Vegge, C. S., Clokie, M. R., and Brøndsted, L. (2014). *Campylobacter jejuni* motility is required for infection by the flagellotropic bacteriophage F341. *Appl. Environ. Microbiol.* 80, 7096–7106. doi: 10.1128/AEM.02057-14
- Brathwaite, K. J., Siringan, P., Connerton, P. L., and Connerton, I. F. (2015). Host adaptation to the bacteriophage carrier state of *Campylobacter jejuni*. *Res. Microbiol.* 166, 504–515. doi: 10.1016/j.resmic.2015.05.003
- Brathwaite, K. J., Siringan, P., Moreton, J., Wilson, R., and Connerton, I. F. (2013). Complete genome sequence of universal bacteriophage host strain *Campylobacter jejuni* subsp. *jejuni* PT14. *Genome Announc.* 1:e00969-13. doi: 10.1128/genomeA.00969-13
- Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Lozupone, C. A., Turnbaugh, P. J., et al. (2011). Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proc. Natl. Acad. Sci. U.S.A.* 108, 4516–4522. doi: 10.1073/pnas.1000080107
- Carvalho, C. M., Gannon, B. W., Halfhide, D. E., Santos, S. B., Hayes, C. M., Roe, J. M., et al. (2010). The *in vivo* efficacy of two administration routes of a phage cocktail to reduce numbers of *Campylobacter coli* and *Campylobacter jejuni* in chickens. *BMC Microbiol.* 10:232. doi: 10.1186/1471-2180-10-232
- Chan, B. K., Abedon, S. T., and Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. *Future Microbiol.* 8, 769–783. doi: 10.2217/fmb.13.47
- Cieplak, T., Soffer, N., Sulakvelidze, A., and Nielsen, D. S. (2018). A bacteriophage cocktail targeting *Escherichia coli* reduces *E. coli* in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota. *Gut Microbes* 9, 391–399. doi: 10.1080/19490976.2018.1447291
- Connerton, P., Carrillo, C. L., Swift, C., Dillon, E., Scott, A., Rees, C., et al. (2004). Longitudinal study of *Campylobacter jejuni* bacteriophages and their hosts from broiler chickens. *Appl. Environ. Microbiol.* 70, 3877–3883. doi: 10.1128/AEM.70.7.3877-3883.2004
- Connerton, P., Timms, A., and Connerton, I. (2011). *Campylobacter* bacteriophages and bacteriophage therapy. *J. Appl. Microbiol.* 111, 255–265. doi: 10.1111/j.1365-2672.2011.05012.x
- Connerton, P. L., Richards, P. J., Lafontaine, G. M., O’Kane, P. M., Ghaffar, N., Cummings, N. J., et al. (2018). The effect of the timing of exposure to *Campylobacter jejuni* on the gut microbiome and inflammatory responses of broiler chickens. *Microbiome* 6:88. doi: 10.1186/s40168-018-0477-5
- Coward, C., Grant, A. J., Swift, C., Philp, J., Towler, R., Heydarian, M., et al. (2006). Phase-variable surface structures are required for infection of *Campylobacter jejuni* by bacteriophages. *Appl. Environ. Microbiol.* 72, 4638–4647. doi: 10.1128/AEM.00184-06
- Dethlefsen, L., Huse, S., Sogin, M. L., and Relman, D. A. (2008). The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol.* 6:e280. doi: 10.1371/journal.pbio.0060280
- Ding, W., Wang, H., and Griffiths, M. W. (2005). Probiotics down-regulate flaa  $\sigma^{28}$  promoter in *Campylobacter jejuni*. *J. Food Protect.* 68, 2295–2300. doi: 10.4315/0362-028X-68.11.2295
- Dufour, N., Delattre, R., Ricard, J.-D., and Debarbieux, L. (2017). The lysis of pathogenic *escherichia coli* by bacteriophages releases less endotoxin than by  $\beta$ -lactams. *Clin. Infect. Dis.* 64, 1582–1588. doi: 10.1093/cid/cix184
- El-Shibiny, A., Scott, A., Timms, A., Metawea, Y., Connerton, P., and Connerton, I. (2009). Application of a group II *Campylobacter* bacteriophage to reduce strains of *Campylobacter jejuni* and *Campylobacter coli* colonizing broiler chickens. *J. Food Protect.* 72, 733–740. doi: 10.4315/0362-028X-72.4.733
- European Food Safety Authority [EFSA] (2010a). Analysis of the baseline survey on the prevalence of *Campylobacter* in broiler batches and of *Campylobacter* and *Salmonella* on broiler carcasses in the EU, 2008 - part A: *Campylobacter* and *Salmonella* prevalence estimates. *EFSA J.* 8:1503. doi: 10.2903/j.efsa.2010.1503
- European Food Safety Authority [EFSA] (2010b). Scientific opinion on quantification of the risk posed by broiler meat to human campylobacteriosis in the EU. *EFSA J.* 8:1437.
- European Food Safety Authority [EFSA]. (2017). The European union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2016. *EFSA J.* 15:e05077.
- Fischer, S., Kittler, S., Klein, G., and Glünder, G. (2013). Impact of a single phage and a phage cocktail application in broilers on reduction of *Campylobacter jejuni* and development of resistance. *PLoS One* 8:e78543. doi: 10.1371/journal.pone.0078543
- Frost, J. A., Kramer, J. M., and Gillanders, S. A. (1999). Phage typing of *Campylobacter jejuni* and *Campylobacter coli* and its use as an adjunct to serotyping. *Epidemiol. Infect.* 123, 47–55. doi: 10.1017/S095026889900254X
- Gormley, F. J., Bailey, R. A., Watson, K. A., McAdam, J., Avendaño, S., Stanley, W. A., et al. (2014). *Campylobacter* colonisation and proliferation in the broiler chicken under natural field challenge is not affected by bird growth rate or breed. *Appl. Environ. Microbiol.* 80, 6733–6738. doi: 10.1128/AEM.02162-14
- Hammerl, J. A., Jäckel, C., Alter, T., Janzycyk, P., Stingl, K., Knüver, M. T., et al. (2014). Reduction of *Campylobacter jejuni* in broiler chicken by successive application of group II and group III phages. *PLoS One* 9:e114785. doi: 10.1371/journal.pone.0114785
- Humphrey, S., Lacharme-Lora, L., Chaloner, G., Gibbs, K., Humphrey, T., Williams, N., et al. (2015). Heterogeneity in the infection biology of *Campylobacter jejuni* isolates in three infection models reveals an invasive

- and virulent phenotype in a st21 isolate from poultry. *PLoS One* 10:e0141182. doi: 10.1371/journal.pone.0141182
- Jäckel, C., Hammerl, J. A., Rau, J., and Hertwig, S. (2017). A multiplex real-time pcr for the detection and differentiation of *Campylobacter* phages. *PLoS One* 12:e0190240. doi: 10.1371/journal.pone.0190240
- Javed, M. A., Ackermann, H.-W., Azeredo, J., Carvalho, C. M., Connerton, I., Evoy, S., et al. (2014). A suggested classification for two groups of *Campylobacter* myoviruses. *Arch. Virol.* 159, 181–190. doi: 10.1007/s00705-013-1788-2
- Kaakoush, N. O., Castaño-Rodríguez, N., Mitchell, H. M., and Man, S. M. (2015). Global epidemiology of *Campylobacter* infection. *Clin. Microbiol. Rev.* 28, 687–720. doi: 10.1128/CMR.00006-15
- Karlyshev, A. V., Ketley, J. M., and Wren, B. W. (2005). The *Campylobacter jejuni* glycome. *FEMS Microbiol. Rev.* 29, 377–390.
- Kittler, S., Fischer, S., Abdulmawjood, A., Glünder, G., and Klein, G. (2013). Effect of bacteriophage application on *Campylobacter jejuni* loads in commercial broiler flocks. *Appl. Environ. Microbiol.* 79, 7525–7533. doi: 10.1128/AEM.02703-13
- Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., and Schloss, P. D. (2013). Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the miseq illumina sequencing platform. *Appl. Environ. Microbiol.* 79, 5112–5120. doi: 10.1128/AEM.01043-1013
- Liang, L., and Connerton, I. F. (2018). FlhF (T368A) modulates motility in the bacteriophage carrier state of *Campylobacter jejuni*. *Mol. Microbiol.* 110, 616–633. doi: 10.1111/mmi.14120
- Lis, L., and Connerton, I. F. (2016). The minor flagellin of *Campylobacter jejuni* (FlaB) confers defensive properties against bacteriophage infection. *Front. Microbiol.* 7:1908. doi: 10.3389/fmicb.2016.01908
- Loc Carrillo, C., Atterbury, R. J., El-Shibiny, A., Connerton, P. L., Dillon, E., Scott, A., et al. (2005). Bacteriophage therapy to reduce *Campylobacter jejuni* colonization of broiler chickens. *Appl. Environ. Microbiol.* 71, 6554–6563. doi: 10.1128/AEM.71.11.6554-6563.2005
- Loc Carrillo, C. M., Connerton, P. L., Pearson, T., and Connerton, I. F. (2007). Free-range layer chickens as a source of *Campylobacter* bacteriophage. *Antonie Van Leeuwenhoek* 92:275. doi: 10.1007/s10482-007-9156-4
- Medzhitov, R. (2007). Recognition of microorganisms and activation of the immune response. *Nature* 449:819. doi: 10.1038/nature06246
- Miernikiewicz, P., Kłopot, A., Soluch, R., Szkuta, P., Kska, W., Hodyra-Stefaniak, K., et al. (2016). T4 phage tail adhesin gp12 counteracts LPS-induced inflammation *in vivo*. *Front. Microbiol.* 7:1112. doi: 10.3389/fmicb.2016.01112
- Newell, D. G., Elvers, K. T., Dopfer, D., Hansson, I., Jones, P., James, S., et al. (2011). Biosecurity-based interventions and strategies to reduce *Campylobacter* spp. on poultry farms. *Appl. Environ. Microbiol.* 77, 8605–8614. doi: 10.1128/AEM.01090-1010
- Osimani, A., Aquilanti, L., Pasquini, M., and Clementi, F. (2017). Prevalence and risk factors for thermotolerant species of *Campylobacter* in poultry meat at retail in Europe. *Poult. Sci.* 96, 3382–3391. doi: 10.3382/ps/pex143
- R Core Team. (2018). *R: A Language and Environment for Statistical Computing*. Vienna: R Foundation for Statistical Computing.
- Ravel, A., Hurst, M., Petrica, N., David, J., Mutschall, S. K., Pintar, K., et al. (2017). Source attribution of human campylobacteriosis at the point of exposure by combining comparative exposure assessment and subtype comparison based on comparative genomic fingerprinting. *PLoS One* 12:e0183790. doi: 10.1371/journal.pone.0183790
- Rosenquist, H., Nielsen, N. L., Sommer, H. M., Nørnung, B., and Christensen, B. B. (2003). Quantitative risk assessment of human campylobacteriosis associated with thermophilic *Campylobacter* species in chickens. *Int. J. Food Microbiol.* 83, 87–103. doi: 10.1016/S0168-1605(02)00317-3
- RStudio Team. (2015). *RStudio: Integrated Development Environment for R*. Boston, MA: RStudio, Inc.
- Sails, A., Wareing, D., Bolton, F., Fox, A., and Curry, A. (1998). Characterisation of 16 *Campylobacter jejuni* and *C. coli* typing bacteriophages. *J. Med. Microbiol.* 47, 123–128. doi: 10.1099/00222615-47-2-123
- Santini, C., Baffoni, L., Gaggia, F., Granata, M., Gasbarri, R., Di Gioia, D., et al. (2010). Characterization of probiotic strains: an application as feed additives in poultry against *Campylobacter jejuni*. *Int. J. Food Microbiol.* 141, S98–S108. doi: 10.1016/j.ijfoodmicro.2010.03.039
- Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., et al. (2009). Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl. Environ. Microbiol.* 75, 7537–7541. doi: 10.1128/AEM.01541-09
- Scott, A. E., Timms, A. R., Connerton, P. L., Carrillo, C. L., Radzum, K. A., and Connerton, I. F. (2007a). Genome dynamics of *Campylobacter jejuni* in response to bacteriophage predation. *PLoS Pathog.* 3:e119. doi: 10.1371/journal.ppat.0030119
- Scott, A. E., Timms, A. R., Connerton, P. L., El-Shibiny, A., and Connerton, I. F. (2007b). Bacteriophage influence *Campylobacter jejuni* types populating broiler chickens. *Environ. Microbiol.* 9, 2341–2353.
- Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., et al. (2011). Metagenomic biomarker discovery and explanation. *Genome Biol.* 12:R60. doi: 10.1186/gb-2011-12-6-r60
- Siringan, P., Connerton, P. L., Cummings, N. J., and Connerton, I. F. (2014). Alternative bacteriophage life cycles: the carrier state of *Campylobacter jejuni*. *Open Biol.* 4:130200. doi: 10.1098/rsob.130200
- Siringan, P., Connerton, P. L., Payne, R. J., and Connerton, I. F. (2011). Bacteriophage-mediated dispersal of *Campylobacter jejuni* biofilms. *Appl. Environ. Microbiol.* 77, 3320–3326. doi: 10.1128/AEM.02704-10
- Sørensen, M. C. H., Alphen, L. B., van Harboe, A., Li, J., Christensen, B. B., Szymanski, C. M., et al. (2011). The f336 bacteriophage recognizes the capsular phosphoramidate modification of *Campylobacter jejuni* NCTC11168. *J. Bacteriol.* 193, 6742–6749. doi: 10.1128/JB.05276-11
- Sulakvelidze, A., and Barrow, P. (2004). “Phage therapy in animals and agribusiness,” in *Bacteriophages: Biology and Application*, eds E. Kutter and A. Sulakvelidze (Boca Raton, FL: CRC Press), 335–380.
- Sulakvelidze, A., and Kutter, E. (2004). “Bacteriophage therapy in humans,” in *Bacteriophages: Biology and Application*, eds E. Kutter and A. Sulakvelidze (Boca Raton: CRC Press), 381–436.
- Tetz, G. V., Ruggles, K. V., Zhou, H., Heguy, A., Tsirigos, A., and Tetz, V. (2017). Bacteriophages as potential new mammalian pathogens. *Sci. Rep.* 7:7043. doi: 10.1038/s41598-017-07278-6
- Thibodeau, A., Fravallo, P., Yergeau, É., Arseneault, J., Lahaye, L., and Letellier, A. (2015). Chicken caecal microbiome modifications induced by *Campylobacter jejuni* colonization and by a non-antibiotic feed additive. *PLoS One* 10:e0131978. doi: 10.1371/journal.pone.0131978
- Torondel, B., Ensink, J. H., Gundogdu, O., Ijaz, U. Z., Parkhill, J., Abdelahi, F., et al. (2016). Assessment of the influence of intrinsic environmental and geographical factors on the bacterial ecology of pit latrines. *Microb. Biotechnol.* 9, 209–223. doi: 10.1111/1751-7915.12334
- Wagenaar, J. A., Van Bergen, M. A., Mueller, M. A., Wassenaar, T. M., and Carlton, R. M. (2005). Phage therapy reduces *Campylobacter jejuni* colonization in broilers. *Vet. Microbiol.* 109, 275–283. doi: 10.1016/j.vetmic.2005.06.002
- Xie, Y., Allaire, J., and Grolemond, G. (2018). *R Markdown: The Definitive Guide*. Boca Raton, FL: Chapman. doi: 10.1201/9781138359444
- Zhang, Z., Schwartz, S., Wagner, L., and Miller, W. (2000). A greedy algorithm for aligning DNA sequences. *J. Comput. Biol.* 7, 203–214. doi: 10.1089/10665270050081478

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Richards, Connerton and Connerton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.